Previous 10 | Next 10 |
DEER PARK, Ill., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report third quarter 2020 financial and o...
DEER PARK, Ill., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,...
The FDA has accepted for review Eton Pharmaceuticals's (ETON) marketing application seeking approval for zonisamide oral suspension, for the treatment of partial seizures in patients with epilepsy.Agency date has been set at May 29, 2021.Zonisamide is one of Eton’s three...
DEER PARK, Ill., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accept...
Eton Pharmaceuticals (ETON) announces the pricing of an underwritten public offering of 2.8M issued shares at a price of $7.00/share.The gross proceeds from the offering are expected to be ~$19.6M.Underwriters' overallotment is an additional 0.42M shares.Closing date is October 16.Net proceed...
DEER PARK, Ill., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the pricing of an underwritten public offering of 2,80...
Eton Pharmaceuticals (ETON) announces public offering to sell common shares.Closing date is October 14, 2020. Net proceeds will be used primarily for general corporate purposes, which may include research and development activities, capital expenditures, selling, general and administrative co...
DEER PARK, Ill. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it is offering to sell shares of its common stoc...
The FDA has accepted application for Eton Pharmaceuticals's (ETON) seeking approval for its dehydrated alcohol injection (DS-100), for the treatment of methanol poisoning.Agency date is set at May 27, 2021.The company filed U.S. application for the injection in July, and it pre...
- Application Assigned a PDUFA Date of May 27, 2021 - Dehydrated Alcohol Injection Market Estimated to be Greater Than $100 Million Annually - Application has Received Orphan Drug Designation for Methanol Poisoning DEER PARK, Ill., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Eton Pharma...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...